Cerebrospinal fluid pro-inflammatory cytokines differe

Journal of Neuroinflammation 15, 305

DOI: 10.1186/s12974-018-1339-6

Citation Report

#	Article	IF	CITATIONS
1	Unequivocal Biomarker for Parkinson's Disease: A Hunt that Remains a Pester. Neurotoxicity Research, 2019, 36, 627-644.	1.3	8
2	Multiple system atrophy – Are cerebrospinal fluid cytokines reliable potential diagnostic marker?. Parkinsonism and Related Disorders, 2019, 65, 1-2.	1.1	1
3	MicroRNAs Dysregulation and Metabolism in Multiple System Atrophy. Frontiers in Neuroscience, 2019, 13, 1103.	1.4	11
4	Frontrunner in Translation: Progressive Supranuclear Palsy. Frontiers in Neurology, 2019, 10, 1125.	1.1	19
5	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	2.8	141
6	Mechanism underlying \hat{I}^2 2-AR agonist-mediated phenotypic conversion of LPS-activated microglial cells. Journal of Neuroimmunology, 2019, 332, 37-48.	1.1	22
7	C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2019, 10, 384.	1.1	61
8	Subthalamic nucleus deep brain stimulation suppresses neuroinflammation by Fractalkine pathway in Parkinson's disease rat model. Brain, Behavior, and Immunity, 2020, 90, 16-25.	2.0	26
9	Microglial Activation and Inflammation as a Factor in the Pathogenesis of Progressive Supranuclear Palsy (PSP). Frontiers in Neuroscience, 2020, 14, 893.	1.4	33
10	Commentary: Discriminating $\hat{l}\pm$ -synuclein strains in parkinson's disease and multiple system atrophy. Frontiers in Neuroscience, 2020, 14, 802.	1.4	1
11	Repurposing Ellipticine Hydrochloride to Combat Colistin-Resistant Extraintestinal Pathogenic E. coli (ExPEC). Frontiers in Microbiology, 2020, 11, 806.	1.5	6
12	Neuroimmune Connections in Aging and Neurodegenerative Diseases. Trends in Immunology, 2020, 41, 300-312.	2.9	111
13	Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. Journal of Neurology, 2021, 268, 2703-2712.	1.8	23
14	Fluid biomarkers in frontotemporal dementia: past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 204-215.	0.9	62
15	Progressive Supranuclear Palsy and Corticobasal Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 151-176.	0.8	10
16	Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain, 2021, 144, 724-745.	3.7	19
17	Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?. Frontiers in Neuroscience, 2020, 14, 580311.	1.4	15
18	The effect of pre-analytical handling on the stability of fractalkine, monocyte chemoattractant protein 1 (MCP1), interleukin 6 and interleukin 8 in samples of human cerebrospinal fluid. Journal of Immunological Methods, 2021, 494, 113057.	0.6	O

#	Article	IF	CITATIONS
19	Diagnosis and treatment for normal pressure hydrocephalus: From biomarkers identification to outcome improvement with combination therapy. Tzu Chi Medical Journal, 2022, 34, 35.	0.4	4
20	Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism and Related Disorders, 2020, 73, 105-116.	1.1	55
21	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 617-625.	0.9	19
22	Inflammation-related gene polymorphisms associated with Parkinson's disease: an updated meta-analysis. Egyptian Journal of Medical Human Genetics, 2020, 21, .	0.5	18
23	Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe Streptococcus suis Infections. Antibiotics, 2021, 10, 26.	1.5	7
24	A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases. Frontiers in Cellular Neuroscience, 2021, 15, 787258.	1.8	62
25	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	3.1	82
26	Update on CSF Biomarkers in Parkinson's Disease. Biomolecules, 2022, 12, 329.	1.8	29
28	A Mendelian randomization study investigating the causal role of inflammation on Parkinson's disease. Brain, 2022, 145, 3444-3453.	3.7	26
29	A Mouse Model of Multiple System Atrophy: Bench to Bedside. Neurotherapeutics, 2023, 20, 117-126.	2.1	3
30	Protective Effects of Ursodeoxycholic Acid Against Oxidative Stress and Neuroinflammation Through Mitogen-Activated Protein Kinases Pathway in MPTP-Induced Parkinson Disease. Clinical Neuropharmacology, 2022, 45, 168-174.	0.2	2
32	The Peripheral Immune Traits Changed in Patients with Multiple System Atrophy. Brain Sciences, 2023, 13, 205.	1.1	1
33	Quantitative and causal analysis for inflammatory genes and the risk of Parkinson's disease. Frontiers in Immunology, 0, 14, .	2.2	4
34	Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease. Aging, 0, , .	1.4	2
43	Free water imaging in Parkinson's disease and atypical parkinsonian disorders. Journal of Neurology, 0, , .	1.8	0